Direct contract access to validated analytical methods, pharmacological screening, animal models, and Phase I–IV clinical trial infrastructures.
GLP-compliant in vivo efficacy verification, pharmacokinetics, metabolic dynamics, and acute/chronic toxicology modeling.
Explore Animal Study
High-throughput isolation and bioassay screening of polysaccharides, alkaloids, flavonoids, and active glycosides.
Explore Screening Specs
ICH Q2(R1) validated HPTLC, HPLC-DAD, and GC-MS fingerprint protocols for chemical consistency and batch release assays.
View Method Services
Quantitative geospatial and harvest-window multi-batch profiling to secure maximum secondary metabolite yield.
View Sourcing Studies
Target receptor affinity, enzyme inhibition, anti-inflammatory pathways, and rapid mechanism-of-action cellular assays.
Explore In Vitro Tests
GCP-compliant human safety, pharmacodynamics, dose escalation, and double-blind multicenter clinical trial execution.
Explore Clinical Trials
Industrial isolation, crystallization, membrane separation, and bulk commercial synthesis of powders, pastes, and oils.
Request OEM Bulk Specs
Full cGMP commercialization of oral liquids, softgels, enteric capsules, micro-tablets, and functional granules.
Request Finished DosageWhy Tier-1 pharmaceutical and nutraceutical innovators are transitioning from fragmented commodity suppliers to vertically integrated CRO-CDMO manufacturing partners.
Unlike small synthetic molecules, botanical active compounds are susceptible to drastic agronomic swings. Seasonal humidity, soil microbial diversity, and geoclimatic variances cause active compound concentration swings exceeding 300%. Sourcing managers require integrated scientific partners capable of geo-origin mapping, seasonal potency quantification, and multi-harvest standardization to guarantee uniform therapeutic efficacy.
Global regulatory bodies—including the United States FDA (21 CFR Part 312 for Botanical Drugs), EMA (HMPC guidelines), and NMPA—demand comprehensive phytochemical identification. Modern supply chains cannot survive on rudimentary non-specific gravimetric or UV-Vis spectrophotometry. Procurement contracts now mandate validated high-performance chromatographic fingerprints (HPLC/HPTLC/GC-MS) with strict impurity profiling for pesticide residues, heavy metals, and residual extraction solvents.
Erecting proprietary GMP-certified extraction suites, supercritical fluid distillation towers, and isolation cleanrooms requires monumental initial CAPEX ($20M–$80M) and protracted validation timelines of 24–36 months. Partnering with an established OEM CDMO converts rigid fixed overhead into variable operational expenses, shielding corporate balance sheets while providing instantaneous access to mature pilot-to-commercial extraction tonnage.
How outsourced research, development, and scalable production create defensible market moats and superior operating margins for healthcare brands.
By leveraging an accumulated database of hundreds of thousands of research batches, MedGence shortens preclinical assay development and formulation screening by 40–60%. Pre-validated chromatographic methods and established cell-line models eliminate trial-and-error bottlenecks, moving botanical candidates from target screening to pilot formulation in record operational timeframes.
Our OEM processes are built strictly upon Quality by Design (QbD) principles. We systematically map Critical Material Attributes (CMAs) of natural botanicals to Critical Process Parameters (CPPs) across counter-current extraction, macroporous resin adsorption, nanofiltration, and spray drying. This ensures uniform critical quality attributes (CQAs) and impeccable lot-to-lot bioequivalence across multi-ton production runs.
Operating under an entrusted contract research and manufacturing model, client intellectual property, novel formulation ratios, custom extraction solvent blends, and specialized therapeutic fractions are kept completely confidential under strict non-disclosure protocols. We function exclusively as your silent scientific engine, never competing with brand clients in commercial retail channels.
Our CDMO capabilities support finished formulations engineered for high bioavailability and user adherence. From enteric-coated softgels and two-piece vegetarian capsules to high-solubility effervescent granules, functional oral liquids, and multi-layer compressed tablets, clients can deploy diverse SKU lines without engaging multiple disconnected co-packers.
Unlike conventional raw ingredient brokers, our scientific CRO infrastructure generates regulatory-grade submission packages. We supply complete toxicological profiles (LD50, Ames genotoxicity, 90-day subchronic toxicity), in vitro mechanistics, rodent model in vivo efficacy data, and human clinical trial reports ready for inclusion in IND, NDA, and dietary supplement structure-function filings.
Every raw herb lot is fully traceable back to its geographical plantation origin, harvest altitude, and seasonal collection window. We conduct comprehensive long-term and accelerated stability testing in compliance with ICH Zone IVb environmental conditions (30°C / 75% RH and 40°C / 75% RH), ensuring global retail shelf-life stability and preventing premature degradation of active polyphenols and saponins.
A proven operational track record delivering breakthrough contract R&D for world-renowned pharmaceutical manufacturers and university hospitals.
A unified, closed-loop CRO-CDMO continuum eliminating data fragmentation between laboratory assays, pilot engineering, and commercial batch delivery.
Targeted isolation and bioassay screening across diverse plant matrixes—including alkaloids, polysaccharides, flavonoids, and terpenes—identifying high-affinity therapeutic fractions while securing commercial viability and ecological sustainability.
View screening scope →
Active metabolite density fluctuates dynamically across ecological microclimates, harvesting periods, and botanical anatomical structures (rhizome vs. leaf vs. seed). We mathematically quantify these variables to lock down an optimal procurement blueprint.
View botanical evaluation →
Validation of regulatory-grade quality control assays. We author chromatographic fingerprints, chiral separations, and quantitative assays using HPTLC, HPLC-DAD, UPLC-MS/MS, and GC-FID compliant with USP, Ph. Eur., and ChP monographs.
View analytical protocols →
Thermodynamic engineering of pretreatment, continuous multi-stage counter-current extraction, resin purification, nanofiltration, and crystallization parameters to maximize active yield while reducing solvent residues and energy consumption.
View extraction research →
Overcoming botanical formulation vulnerabilities including hygroscopicity, poor aqueous solubility, thermal instability, and unpleasant organoleptic profiles to ensure stability and smooth high-speed commercial packaging.
View formulation process →
Comprehensive GLP toxicological evaluations: median lethal dose (LD50), acute oral toxicity, 28/90-day repeated-dose subchronic toxicity, Ames reverse mutation genotoxicity, and in vivo chromosomal aberration assays.
View toxicology studies →
Rapid, high-throughput primary and immortalized cell culture assays exploring molecular pathway regulation (e.g., NF-κB, AMPK, Nrf2), anti-inflammatory cytokine expression, and antioxidant enzyme elevation.
View in vitro assays →
Validated disease models in rodents (metabolic syndrome, cognitive decline, hepatoprotection, osteoarthritis) generating vital pharmacokinetic, tissue distribution, and bio-efficacy data required before human trials.
View animal pharmacology →
End-to-end clinical trial management: protocol authoring, IRB/ethics submissions, GCP monitoring, biostatistical analysis, and clinical study reports (CSR) for dietary supplement efficacy claims or pharmaceutical NDA approvals.
View clinical scope →
Modernization of classical TCM polyherbal formulations using network pharmacology and pharmacokinetic compatibility principles, optimizing multi-target synergistic efficacy and eliminating ingredient antagonism.
View formulation research →
Commercial-scale supply of isolated botanical active ingredients, high-potency standardized extract powders, concentrated liquids, vacuum-purified pastes, and supercritical steam-distilled volatile oils under strict cGMP control.
Request bulk ingredient specs →
High-capacity packaging and dosage manufacturing for global export: automated encapsulation (hard/soft), fluid-bed granulation, tablet pressing, sterile oral liquids, and modern pouching with global tamper-evident labeling.
Request finished dosage catalog →Integrating artificial intelligence, continuous green extraction, and multi-omics profiling to define the next frontier of botanical medicine manufacturing.
Deploying machine-learning molecular docking models across proprietary phytochemical libraries, predicting target-ligand affinities and synergistic botanical interactions before committing laboratory resources.
Replacing traditional batch reflux with continuous counter-current supercritical CO2 and ultrasound-assisted aqueous fractionation, reducing carbon intensity by 45% and eliminating organic solvent waste streams.
Embedding real-time Near-Infrared (NIR) and Raman spectroscopy sensors across distillation columns and spray dryers for continuous Process Analytical Technology (PAT) monitoring, preventing out-of-spec batches.
Developing liposomal, phytosome, and self-emulsifying drug delivery systems (SEDDS) for poorly permeable natural polyphenols (curcumin, resveratrol, quercetin), multiplying gastrointestinal systemic absorption by 500%–1200%.
Ensuring frictionless compliance and inspection readiness across US, European, Asia-Pacific, and domestic regulatory frameworks.
Our regulatory affairs division compiles Common Technical Document (CTD) Module 3 (Quality/Chemistry, Manufacturing, and Controls) and Drug Master Files (Type IV/Type II DMFs), streamlining customer filings with the US FDA, Health Canada (NHPD), and European Medicines Agency (EMA).
We provide full audit defense readiness for international client quality assurance audits, US FDA cGMP (21 CFR Part 111 / 211) inspections, and ISO/HACCP certifications. All batch manufacturing records (BMR) and analytical data are fully compliant with ALCOA+ data integrity principles.
Navigating international phytosanitary permits, CITES clearances for protected botanicals, and testing certificates for residual ethylene oxide, irradiation, polycyclic aromatic hydrocarbons (PAHs), and heavy metals to ensure immediate customs port release without border hold delays.
Our scientific foundation powers over 100 enterprise healthcare manufacturers, university medical centers, and national clinical TCM research institutions.
Tongrentang Group
CR Sanjiu
Sunflower Pharma
Livzon Pharma
Dihon Pharma
Golden Throat Group
Yangtze River Pharma
Beihai Gofar Biological
Humanwell Healthcare
SCIMYTH Pharma
Shandong Hanfang
Luoxin Pharma
Zhongsheng Pharma
Brilliance & Abundance
Apeloa Pharma
Hunan Heng Chang
Baotou TCM
Kamp Medicine
Guangxi Santo
Kangshou Pharma
Jiangxi Juwang
Beijing Tcmages
Guizhou Ruihe
CR Jinchan Pharma
Kangmei Pharma
Tianjicaotang Pharma
Kingstone Unite
Shuguang Hospital
Hunan Affiliated TCM
1st Hosp. Hunan TCM Univ.
2nd Xiangya Hospital CSU
2nd Hosp. Hunan TCM Univ.
Orthopedics TCM Zhuzhou
Comprehensive technical and legal insights for procurement directors, Chief Scientific Officers, and regulatory heads evaluating our manufacturing partnership.
Standard botanical vendors function primarily as commodity ingredient traders, competing on basic biomass pricing with limited quality controls beyond simple UV-Vis content assays. MedGence operates as a fully integrated Contract Research and Development Organization (CRO) and Contract Development and Manufacturing Organization (CDMO).
Our scientific team of over 300 researchers directly manages the complete pipeline: from initial botanical raw-material screening, origin and seasonal potency evaluation, and development of validated chromatographic fingerprints (HPLC, HPTLC, GC-MS), to GLP toxicological profiling, in vitro and in vivo animal studies, and Phase I–IV clinical trials. Because our pilot plant and collaborative manufacturing facilities are directly supervised by our technical scientists, validated laboratory results transition seamlessly into commercial-scale cGMP manufacturing without knowledge loss.
Intellectual Property (IP) preservation is the bedrock of our business model. MedGence operates on an entrusted, fee-for-service research and contract manufacturing paradigm under comprehensive non-disclosure and confidentiality agreements (NDAs).
All product formulas, extraction solvent matrices, temperature profiles, purification chromatography sequences, and customized clinical findings developed under contract remain the 100% exclusive intellectual property of the commissioning client. MedGence does not market or retail proprietary branded formulations in consumer retail channels, eliminating channel conflict and preserving our partners' long-term competitive moat.
To eliminate the variability inherent in natural botanical harvests, we establish multi-compound chemical fingerprints using high-performance thin-layer chromatography (HPTLC) for qualitative botanical identity confirmation, alongside high-performance liquid chromatography coupled with diode array detectors (HPLC-DAD) or mass spectrometry (LC-MS/MS) for precise active quantitative assays.
For volatile constituents, we deploy gas chromatography with flame ionization or mass detection (GC-FID/GC-MS). Furthermore, each commercial release lot undergoes rigorous screening for environmental contaminants: multi-residue pesticide screening (over 400 pesticides), heavy metal ICP-MS quantification (lead, cadmium, arsenic, mercury), aflatoxin assays, residual solvent analysis via headspace GC, and pharmacopeial microbiological testing.
At the bulk active ingredient level, we supply ultra-pure isolated fractions, standardized ratio extracts, high-concentration liquids, vacuum-dried pastes, micro-encapsulated spray-dried powders, and steam/supercritical CO2 distilled volatile essential oils.
At the finished commercial dosage level, our cGMP-certified partner packaging lines produce oral liquids and tonics, hard two-piece vegetarian and gelatin capsules, enteric softgels, multi-layer compressed tablets, chewable pastilles, effervescent granules, and vacuum-sealed soluble drink mixes ready for immediate retail distribution.
Yes. MedGence has supported over 100 leading pharmaceutical enterprises and academic hospitals, contributing to the development of 22 innovative natural medicines and 56 hospital preparation registrations. We design and execute complete preclinical packages: acute and 90-day subchronic toxicity studies, genotoxicity batteries (Ames, micronucleus), and animal efficacy models.
For human validation, we design small-cohort randomized clinical trials for dietary supplement efficacy claims, as well as multi-center GCP-compliant Phase I safety/pharmacokinetics and Phase II–IV double-blind, placebo-controlled efficacy trials required for new drug applications (NDAs).
Because of our vast historical formulation repository spanning 83 classic modernized formulas and approximately 400 single-herb monographs, our discovery and screening phases are exceptionally swift. Standard analytical method validation and bench-top pilot extraction are typically achieved within 4 to 8 weeks.
Preclinical toxicological and in vitro bioassays require 8 to 14 weeks depending on the study breadth. Commercial scale-up, validation batches (3 consecutive GMP conformance lots), and release testing for bulk actives or finished dosage formats generally span 6 to 12 weeks following pilot approval.
Direct contract access to our laboratory screening suites, pilot extraction lines, and commercial manufacturing facilities.
GLP-certified rodent model validation, in vivo pharmacodynamics, tissue bioavailability, and subchronic toxicology testing.
Request Animal Study Quote
Target-directed chemical extraction and isolation across rare botanical taxa to substantiate therapeutic candidate fractions.
Request Screening Protocol
Authoring robust analytical fingerprints (HPLC, HPTLC, GC) with full validation protocols for global regulatory filings.
Order Method Development
Precision field sampling and chemical density analytics across regional provenances and harvest seasons.
Commission Origin Study
Cell-based mechanistic screening, enzymatic inhibition, cytokine suppression, and high-throughput potency assays.
Request In Vitro Package
Multicenter clinical trials, small human cohort proof-of-concept studies, and NDA statistical reporting under GCP.
Initiate Clinical Trial
Continuous counter-current extraction and purification of bioactive botanical powders, pastes, and essential oils.
Request Bulk Quotation
High-speed commercial encapsulation, tableting, granule sachet packaging, and liquid filling in GMP cleanrooms.
Request Finished Dosage RFPWhether you require targeted active ingredient screening, GLP toxicological validation, clinical trial execution, or high-volume commercial finished dosage manufacturing, our technical leadership team is prepared to scope your study package.
